CAP 2

Continued Access to PREVAIL (CAP2)- WATCHMAN Left Atrial Appendage (LAA) Closure Technology

CAP 2 [NCT01760291]

Description: To provide additional information about the safety and efficacy of the WATCHMAN LAA Closure Technology

Device: WATCHMAN LAA Closure Technology

Primary Investigator: Gupta

Drug/Device Information
WATCHMAN device is implanted at or slightly distal to the opening of the LAA (Left Atrial Appendage)
Prevent embolization of blood clots formed within the trabeculated LAA.
Non-randomized study to allow continued access to the WATCHMAN LAA Closure Technology
Boston Scientific
Major Inclusion and Exclusion
Non valvular AF and eligible for Warfarin
Able to be off Warfarin if LAA is sealed
CHADS2 score of 2 or greater
Must be Medicare patients